Team DMI was one of five teams who received a milestone prize at the Qualcomm Connect 2016 conference. Originally the competition started with over 300 teams and it was then reduced to ten and now five. “We are thrilled to be part of this elite group of contestants. We entered this competition because of the shared goal for democratization of healthcare. The rHEALTH technology is core to our entry with its capabilities in small volume blood analysis,” said Dr. Eugene Chan.
This week, the rHEALTH ONE received a patent issuance from the United States Patent and Trademark Office. This patent issuance acknowledges the unique design of the biomedical instrument, including its small form factor, novel sample loading mechanism for microvolumes, and low power. The rHEALTH ONE utilizes the matchbox-sized cytometry module, microparticles, and small volume sample handling to allow a breadth of biomarker and cell analyses. The patent issuance further strengthens DMI’s intellectual property portfolio for its technology.
Eugene Y. Chan, MD, DMI Founder presented a poster titled, rHEALTH X Technology for Comprehensive Biomedical Analysis at NASA’s 2016 Human Research Program Investigator’s Workshop. The poster highlighted the broad analytical capabilities of the rHEALTH X platform, including measurement of non-invasive vitals signs and blood-based biomarker measurements. The rHEALTH X is designed for long-duration space travel, allowing astronauts to perform medical diagnoses without the need for a skilled medical professional. These capabilities will simultaneously advance terrestrial diagnoses by consumers and medical professionals alike.
Eugene Y. Chan, MD gave an invited talk on the rHEALTH technology at this year’s AACC Emerging Clinical & Laboratory Diagnostics: Pushing the Envelope conference in Los Angeles November 4, 2015. The title of his talk is rHEALTH Sensor for Small Volume, Multiplexed Blood Analysis.
Cambridge, MA – DMI announced today that its spiral vortexer micromixer is now patented. It formally issued as a patent titled, “Microfluidic Passive Mixing Chip” as US Patent No. 9,194,780. The patent protects a novel means of mixing large blood cells in a microfluidic environment. Traditional microfluidic mixers have a difficult time with blood since blood is a lot larger and less diffusion than conventional reagents. Multiple mixing forces are imparted onto blood samples using the spiral vortexer micromixer. This technology was developed with support from NASA and has been tested in zero gravity onboard parabolic flights.
This week, Dr. Eugene Chan joined a group of doctors, scientists and company leaders at the Enabling POC Dx Conference to give a talk about DMI’s rHEALTH sensor.
Alice Park (TIME) writes about how blood tests are changing medicine as the range of blood-detectable conditions grow because of new diagnostic technologies.
DMI, one of the ten finalists in the Qualcomm Tricorder XPRIZE has delivered its first Tricorder prototype to the competition this past weekend. The Qualcomm Tricorder XPRIZE is a $10 Million competition in which the final participants have to deliver a comprehensive medical device inspired by the Star Trek Tricorder.
DMI’s rHealth Tricorder is geared to diagnose 15 different medical conditions and 6 vital signs, all by consumers themselves. The technology includes a blood analyzing system, a vitals patch with continuous monitoring capabilities and other point-of-care tests to match the required competition guidelines. By June 1, 30 additional units will be delivered by the team. These will go through a 6 month period of consumer testing before the winner will be announced in 2016.
Under a procurement for utilization of the International Space Station, DMI will develop its rHEALTH X technology for astronaut crew member use. The rHEALTH X technology is particularly well-suited for long-duration space travel and will allow crew members to monitor their own health in an autonomous manner. The Cambridge based company has been selected for a Phase II follow-on contract in an effort to further develop the technology bringing it one step closer to space.
Watch at http://www.jove.com/video/51743/reduced-gravity-environment-hardware-demonstrations-prototype
Dr. Eugene Chan speaks with Not Impossible Now about the rHEALTH technology. Read more http://www.notimpossiblenow.com/lives/compact-device-can-diagnose-hundreds-of-diseases-with-just-a-drop-of-blood
Watch interview with Dr. Eugene Chan and Peter Diamadis here http://video.cnbc.com/gallery/?video=3000327128&play=1
Read more at https://www.wired.com/2014/11/device-diagnoses-hundreds-diseases-using-single-drop-blood/
The DNA Medicine Insitute (DMI) announced today that it has been awarded a contract from NASA to develop non-invasive capabilities for the rHEALTH platform. This platform is called the rHEALTH X, which is based on technology to measure a plethora of values from a single drop of blood, bodily fluid, or sample.
“We are thrilled to receive this contract award from NASA and to add non-invasive capabilities to our core rHEALTH technology. It is our aim to develop a single, handheld device that allows all-encompassing biomedical diagnostic measurements for astronauts for the International Space Station and long-duration space travel to Mars and other challenging destinations. It is vital that astronauts be able to perform autonomous diagnosis for every possible lab value in order to maximize the probability of mission success. NASA has been a strong supporter of the technology and we are grateful for the opportunity to develop a technology for our astronauts,” commented Eugene Y. Chan, MD, Principal Investigator of the contract.
In particular, the contract will fund the development of EKG, respiratory rate, SpO2, and temperature measurements. It is envisioned that the technology will work in conjunction with the rest of the rHEALTH technology, thereby augmenting its capabilities for these important vital signs.
The rHEALTH Sensor was recently featured in a publication in the Journal of Personallized Medicine. This pioneering work by Dr. Patrick Gladding summarizes key technologies relating to therapeutics and diagnostics (or theranostics) for cardiovascular medicine.
Abstract: It is undeniable that the increasing costs in healthcare are a concern. Although technological advancements have been made in healthcare systems, the return on investment made by governments and payers has been poor. The current model of care is unsustainable and is due for an upgrade. In developed nations, a law of diminishing returns has been noted in population health standards, whilst in the developing world, westernized chronic illnesses, such as diabetes and cardiovascular disease have become emerging problems. The reasons for these trends are complex, multifactorial and not easily reversed. Personalized medicine has the potential to have a significant impact on these issues, but for it to be truly successful, interdisciplinary mass collaboration is required. We propose here a vision for open-access advanced analytics for personalized cardiac diagnostics using imaging, electrocardiography and genomics.